DRKS00016024CompletedNot Applicable
Phase 1-3 development of an EORTC module assessing fertility issues and patient care needs - EORTC - Fertility
Interdisziplinäres Tumorzentrum - CCCF - Stiftungsprofessur Selbsthilfeforschung0 sites82 target enrollmentStarted: February 4, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 82
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to one (—)
- Sex
- All
Inclusion Criteria
- •Patients are eligible if they have / are
- •signed the written informed consent to participate in the study
- •a primary diagnosis of
- •o gynaecological cancer
- •o bladder cancer
- •o colorectal cancer
- •o testicular cancer
- •o prostate cancer
- •o breast cancer
- •o sarcoma and
- •Female patients > 18 years to 42 years
- •Female patients in pre-menopause
- •Male patients > 18 years
- •Patients in any treatment with curative intention affecting fertility, focusing on
- •o Systemic therapy
- •o Radiotherapy
- •o Combined therapy (radiation, surgery, systemic treatment)
Exclusion Criteria
- •Patients with other than the above mentioned diagnoses and treatments, that are contradictionnairy to the inclusion criteria
Investigators
Similar Trials
Not yet recruiting
Not Applicable
ursing interventions for Heart failure patientsCTRI/2018/05/014047Advance Cardiac Centre
Not yet recruiting
Phase 1
Development of Quality of Life Questionnaire in Gastric CancersCTRI/2021/02/031117niversity of Southampton
Completed
Not Applicable
Evaluation of a bespoke e-health platform on general health and wellbeing in young Australians: a pilot studyACTRN12616000163404niversity of Sydney300
Not yet recruiting
Not Applicable
The missing link: optimizing return-to-work for employees with cancer, by supporting employersNL-OMON23290Amsterdam UMC, location AMC / University of Amsterdam (UvA) and University Maastricht (UM).
Active, not recruiting
Phase 1
The effect of lanreotide on therapy resistant gastro-esophageal refluxpatients with persistent endoscopic reflux in spite of maximal medical therapy with PPI 2 x 40 mg pantoprazole before breakfast and dinner and 300 mg of H2 blocker ranitidine at bedtime AND continuing pathological reflux proven on impedancemetry.MedDRA version: 14.1Level: LLTClassification code 10017924Term: Gastroesophageal refluxSystem Organ Class: 100000004856EUCTR2013-004232-29-BEZ Brussel15